Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhRMA nudges BIO on marketing code

Executive Summary

Billy Tauzin, president of the Pharmaceutical Research and Manufacturers of America, is continuing to publicly pressure Jim Greenwood, president of Biotechnology Industry Organization, to adopt PhRMA's marketing code. BIO has been considering it, but says the code may be a difficult fit because few of its members market products and the products promoted are complex (1"The Pink Sheet" DAILY, Nov. 18, 2008). At a briefing for reporters Jan. 14, Tauzin said, "Jim tells me ... [that] sometime in February or March they are planning to make a decision, and hopefully they'll endorse the code." For its part, BIO said, "We have no specific timetable set for this discussion.

You may also be interested in...

BIO Continues To Mull PhRMA’s Marketing Code

Limits on physician interactions might not be appropriate when trying to educate doctors on complex, large-molecule products, the biotech group believes.

Sickle Cell Gene Therapy May Need New US-Backed Payment Program, Grogan Suggests

Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts